squiffy2
06-20-2008, 07:14 AM
A pilot study of LDN therapy in MS was carried out by the Milan neurological researcher, Dr. Maira Gironi in 2007.
Dr. Gironi's research team has long been a locus for significant research on endorphins in relation to illness, and this study tracked accurate assessments of the patients' beta-endorphin levels in response to their LDN treatment.
This was a 6-month pilot, multicentric, open-label, therapeutic study of 40 patients with Primary Progressive Multiple Sclerosis (PPMS) between the age of 18 and 60. The subjects were over 3 and less than 6 on the expanded disability severity scale (EDSS). They were affected with spasticity, pain, and/or fatigue. Optimisation of gabaergic or serotoninergic drugs before entering the study was requested. Any opioid-containing drug, immunosuppressive or immunomodulator medicines were not allowed.
All 40 patients were treated with LDN at a final dose of 5 mg after a 2-week titration of 2.5 mg. Common involvement of the spinal cord mostly in the primary progressive form of MS explains a high prevalence of spasticity, pain, and fatigue accompanying the disease. People with PPMS are known to have low levels of beta-endorphins and a possible mild, diffuse inflammatory reaction. Conventional anti-inflammatory drugs seem to fail to cross the blood brain barrier in people with PPMS...............................
For the full article please go to MSRC: MS Research News : Drugs : Low Dose Naltrexone - Latest News (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1306)
Dr. Gironi's research team has long been a locus for significant research on endorphins in relation to illness, and this study tracked accurate assessments of the patients' beta-endorphin levels in response to their LDN treatment.
This was a 6-month pilot, multicentric, open-label, therapeutic study of 40 patients with Primary Progressive Multiple Sclerosis (PPMS) between the age of 18 and 60. The subjects were over 3 and less than 6 on the expanded disability severity scale (EDSS). They were affected with spasticity, pain, and/or fatigue. Optimisation of gabaergic or serotoninergic drugs before entering the study was requested. Any opioid-containing drug, immunosuppressive or immunomodulator medicines were not allowed.
All 40 patients were treated with LDN at a final dose of 5 mg after a 2-week titration of 2.5 mg. Common involvement of the spinal cord mostly in the primary progressive form of MS explains a high prevalence of spasticity, pain, and fatigue accompanying the disease. People with PPMS are known to have low levels of beta-endorphins and a possible mild, diffuse inflammatory reaction. Conventional anti-inflammatory drugs seem to fail to cross the blood brain barrier in people with PPMS...............................
For the full article please go to MSRC: MS Research News : Drugs : Low Dose Naltrexone - Latest News (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1306)